Serum aryl hydrocarbon receptor activity ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis.
Auteur(s) :
Yamazaki, Tomoo [Auteur]
Kouno, Tetsuya [Auteur]
Hsu, Cynthia L. [Auteur]
Hartmann, Phillipp [Auteur]
Mayo, Susan [Auteur]
Zhang, Xinlian [Auteur]
Stärkel, Peter [Auteur]
Bosques-Padilla, Francisco [Auteur]
Verna, Elizabeth C. [Auteur]
Abraldes, Juan G. [Auteur]
Brown, Robert S. [Auteur]
Vargas, Victor [Auteur]
Altamirano, Jose [Auteur]
Caballería, Juan [Auteur]
Shawcross, Debbie L. [Auteur]
Louvet, Alexandre [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Lucey, Michael R. [Auteur]
Mathurin, Philippe [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Garcia-Tsao, Guadalupe [Auteur]
Bataller, Ramon [Auteur]
Schnabl, Bernd [Auteur]
Kouno, Tetsuya [Auteur]
Hsu, Cynthia L. [Auteur]
Hartmann, Phillipp [Auteur]
Mayo, Susan [Auteur]
Zhang, Xinlian [Auteur]
Stärkel, Peter [Auteur]
Bosques-Padilla, Francisco [Auteur]
Verna, Elizabeth C. [Auteur]
Abraldes, Juan G. [Auteur]
Brown, Robert S. [Auteur]
Vargas, Victor [Auteur]
Altamirano, Jose [Auteur]
Caballería, Juan [Auteur]
Shawcross, Debbie L. [Auteur]
Louvet, Alexandre [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Lucey, Michael R. [Auteur]
Mathurin, Philippe [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Garcia-Tsao, Guadalupe [Auteur]
Bataller, Ramon [Auteur]
Schnabl, Bernd [Auteur]
Titre de la revue :
Hepatology (Baltimore, Md.)
Nom court de la revue :
Hepatology
Numéro :
80
Pagination :
403-417
Date de publication :
2024-08
ISSN :
1527-3350
Mot(s)-clé(s) en anglais :
Gut microbiota
tryptophan metabolites
alcohol-related liver disease
bacteria
tryptophan metabolites
alcohol-related liver disease
bacteria
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background and Aims:
Patients with alcohol-associated hepatitis (AH) have an altered fecal metabolome, including reduced microbiota-derived tryptophan metabolites, which function as ligands for aryl hydrocarbon receptor ...
Lire la suite >Background and Aims: Patients with alcohol-associated hepatitis (AH) have an altered fecal metabolome, including reduced microbiota-derived tryptophan metabolites, which function as ligands for aryl hydrocarbon receptor (AhR). The aim of this study was to assess serum AhR ligand activity in patients with AH. Approach and Results: The study included 74 controls without AUD, 97 patients with AUD, and 330 patients with AH from 2 different multicenter cohorts (InTeam: 134, AlcHepNet: 196). Serum AhR activity was evaluated using an AhR reporter assay with HepG2-Lucia cells incubated with serum for 24 hours. Serum AhR activity was significantly higher in patients with AH compared with both controls (1.59 vs. 0.96-fold change, p < 0.001) and patients with AUD (1.59 vs. 0.93, p < 0.001). In both AH cohorts, patients with AhR activity ≥ 2.09 had significantly lower cumulative survival rates at 30, 60, 90, and 180 days compared to those with AhR activity < 2.09. When serum AhR activity was used to further stratify patients with severe AH, the cumulative 30, 60, 90, and 180-day survival rates for patients with severe AH and the AhR activity ≥ 2.09 group were all significantly lower than those with an AhR activity < 2.09 group. Conclusions: Serum AhR activity was significantly higher in patients with AH compared with controls and individuals with AUD, and this increased activity was associated with higher mortality. Consequently, serum AhR activity holds potential as a prognostic marker.Lire moins >
Lire la suite >Background and Aims: Patients with alcohol-associated hepatitis (AH) have an altered fecal metabolome, including reduced microbiota-derived tryptophan metabolites, which function as ligands for aryl hydrocarbon receptor (AhR). The aim of this study was to assess serum AhR ligand activity in patients with AH. Approach and Results: The study included 74 controls without AUD, 97 patients with AUD, and 330 patients with AH from 2 different multicenter cohorts (InTeam: 134, AlcHepNet: 196). Serum AhR activity was evaluated using an AhR reporter assay with HepG2-Lucia cells incubated with serum for 24 hours. Serum AhR activity was significantly higher in patients with AH compared with both controls (1.59 vs. 0.96-fold change, p < 0.001) and patients with AUD (1.59 vs. 0.93, p < 0.001). In both AH cohorts, patients with AhR activity ≥ 2.09 had significantly lower cumulative survival rates at 30, 60, 90, and 180 days compared to those with AhR activity < 2.09. When serum AhR activity was used to further stratify patients with severe AH, the cumulative 30, 60, 90, and 180-day survival rates for patients with severe AH and the AhR activity ≥ 2.09 group were all significantly lower than those with an AhR activity < 2.09 group. Conclusions: Serum AhR activity was significantly higher in patients with AH compared with controls and individuals with AUD, and this increased activity was associated with higher mortality. Consequently, serum AhR activity holds potential as a prognostic marker.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Date de dépôt :
2024-05-06T21:46:10Z
2024-08-21T14:56:16Z
2024-08-21T14:56:16Z